Clinical Trials Browser

Completed × OTHER × Respiratory Tract Diseases × Clear all

Cardiovascular Diseases, Disease, Embolism, Lung Diseases, Neoplasms, Pulmonary Embolism, Respiratory Tract Diseases, Vascular Diseases, Embolism and Thrombosis

NCT02904954 2023-10-11

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Phase 2 Completed

60 enrolled 12 charts

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT01860898 2022-09-28

A Phase I Study of iPS Cell Generation From Patients With COPD

Phase NA Completed

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Obstructive, Lung Neoplasms, Neoplasms, Pulmonary Emphysema, Respiratory Tract Diseases, Thoracic Diseases, Carcinoma, Small Cell, Pulmonary Disease, Chronic Obstructive

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Thoracic

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT02406053 2015-04-02

Oxidative Damage and Antioxidant Mechanisms in COPD

Completed

111 enrolled

Thoracic

Lung Neoplasms, Respiratory Tract Diseases

Clinical Trials

HYDRA

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

A Phase I Study of iPS Cell Generation From Patients With COPD

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Oxidative Damage and Antioxidant Mechanisms in COPD